Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung

L. L. Porter, D. H. Johnson, J. D. Hainsworth, K. R. Hande, F. A. Greco

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Twenty-nine patients with refractory recurrent small cell carcinoma of the lung were treated with cisplatin (40 mg/m2) and etoposide (200 mg/m2) each day for 3 days, repeated every 3-4 weeks. Fifteen of these patients had received etoposide in their original treatment regimen. Fifteen (52%) of all patients had a major response, as did nine (60%) of the patients with prior exposure to etoposide. Myelotoxicity was moderately severe. The median duration of responses was 3 months (range, 6-36 weeks). This study suggests synergism between cisplatin and etoposide. The toxicity seen in this heavily pretreated group of patients suggests that smaller doses be studied in this group. The synergism may be best utilized in the initial regimens against small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)479-481
Number of pages3
JournalCancer Treatment Reports
Volume69
Issue number5
StatePublished - 1985

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Combination Drug Therapy
Cisplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Porter, L. L., Johnson, D. H., Hainsworth, J. D., Hande, K. R., & Greco, F. A. (1985). Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treatment Reports, 69(5), 479-481.

Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. / Porter, L. L.; Johnson, D. H.; Hainsworth, J. D.; Hande, K. R.; Greco, F. A.

In: Cancer Treatment Reports, Vol. 69, No. 5, 1985, p. 479-481.

Research output: Contribution to journalArticle

Porter, LL, Johnson, DH, Hainsworth, JD, Hande, KR & Greco, FA 1985, 'Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung', Cancer Treatment Reports, vol. 69, no. 5, pp. 479-481.
Porter, L. L. ; Johnson, D. H. ; Hainsworth, J. D. ; Hande, K. R. ; Greco, F. A. / Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 5. pp. 479-481.
@article{aee59c9ba9af4b408dcd762c5b94e861,
title = "Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung",
abstract = "Twenty-nine patients with refractory recurrent small cell carcinoma of the lung were treated with cisplatin (40 mg/m2) and etoposide (200 mg/m2) each day for 3 days, repeated every 3-4 weeks. Fifteen of these patients had received etoposide in their original treatment regimen. Fifteen (52{\%}) of all patients had a major response, as did nine (60{\%}) of the patients with prior exposure to etoposide. Myelotoxicity was moderately severe. The median duration of responses was 3 months (range, 6-36 weeks). This study suggests synergism between cisplatin and etoposide. The toxicity seen in this heavily pretreated group of patients suggests that smaller doses be studied in this group. The synergism may be best utilized in the initial regimens against small cell lung cancer.",
author = "Porter, {L. L.} and Johnson, {D. H.} and Hainsworth, {J. D.} and Hande, {K. R.} and Greco, {F. A.}",
year = "1985",
language = "English (US)",
volume = "69",
pages = "479--481",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung

AU - Porter, L. L.

AU - Johnson, D. H.

AU - Hainsworth, J. D.

AU - Hande, K. R.

AU - Greco, F. A.

PY - 1985

Y1 - 1985

N2 - Twenty-nine patients with refractory recurrent small cell carcinoma of the lung were treated with cisplatin (40 mg/m2) and etoposide (200 mg/m2) each day for 3 days, repeated every 3-4 weeks. Fifteen of these patients had received etoposide in their original treatment regimen. Fifteen (52%) of all patients had a major response, as did nine (60%) of the patients with prior exposure to etoposide. Myelotoxicity was moderately severe. The median duration of responses was 3 months (range, 6-36 weeks). This study suggests synergism between cisplatin and etoposide. The toxicity seen in this heavily pretreated group of patients suggests that smaller doses be studied in this group. The synergism may be best utilized in the initial regimens against small cell lung cancer.

AB - Twenty-nine patients with refractory recurrent small cell carcinoma of the lung were treated with cisplatin (40 mg/m2) and etoposide (200 mg/m2) each day for 3 days, repeated every 3-4 weeks. Fifteen of these patients had received etoposide in their original treatment regimen. Fifteen (52%) of all patients had a major response, as did nine (60%) of the patients with prior exposure to etoposide. Myelotoxicity was moderately severe. The median duration of responses was 3 months (range, 6-36 weeks). This study suggests synergism between cisplatin and etoposide. The toxicity seen in this heavily pretreated group of patients suggests that smaller doses be studied in this group. The synergism may be best utilized in the initial regimens against small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021868156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021868156&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 479

EP - 481

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -